Table 4:
Evaluation of treatment relations derived from the i2b2 test set
| Configuration | System | P | R | F |
|---|---|---|---|---|
| UTD | 76.08 | 83.83 | 79.77 | |
| SemRep | 84.50 | 19.16 | 31.23 | |
| MEDI-ALL | ||||
| Core | MEDI | 77.23 | 27.42 | 40.47 |
| MEDI and SemRep | 94.92 | 9.84 | 17.83 | |
| MEDI or SemRep | 76.84 | 36.73 | 49.70 | |
| Hyponym | MEDI | 42.83 | 34.62 | 38.29 |
| MEDI and SemRep | 92.00 | 12.13 | 21.43 | |
| MEDI or SemRep | 46.11 | 41.65 | 43.77 | |
| MEDI-HPS | ||||
| Core | MEDI | 83.85 | 23.73 | 36.99 |
| MEDI and SemRep | 94.12 | 8.44 | 15.48 | |
| MEDI or SemRep | 82.01 | 34.45 | 48.51 | |
| Hyponym | MEDI | 59.73 | 30.76 | 40.60 |
| MEDI and SemRep | 92.42 | 10.72 | 19.21 | |
| MEDI or SemRep | 62.64 | 39.19 | 48.22 | |
The configuration of MEDI-related systems included the Level 3 medication expansion.
F, F1-measure; HPS, high-precision subset; MEDI, medication indication; P, precision; R, recall; UTD, University of Texas at Dallas.